Maxdulin 75/30 Capsule DR is a combination pharmaceutical formulation containing Pregabalin 75 mg and Duloxetine 30 mg, designed for the management of neuropathic pain and certain mood disorders. Pregabalin, an anticonvulsant and analgesic agent, modulates calcium channels in the central nervous system, reducing neurotransmitter release and thereby alleviating neuropathic pain symptoms such as burning, shooting pain, and allodynia. Duloxetine, a selective serotonin and norepinephrine reuptake inhibitor (SNRI), enhances the inhibitory pain pathways and is effective in treating major depressive disorder and generalized anxiety disorder, in addition to its analgesic properties. The delayed-release (DR) formulation ensures gradual drug release, improving tolerability and maintaining therapeutic plasma concentrations over an extended period. Maxdulin 75/30 is indicated for patients requiring combined therapy for chronic neuropathic pain conditions, including diabetic peripheral neuropathy and fibromyalgia, especially when accompanied by depressive symptoms. The combination targets multiple pain pathways, offering enhanced efficacy compared to monotherapy. Caution is advised in patients with hepatic or renal impairment, and potential side effects include dizziness, somnolence, dry mouth, and gastrointestinal disturbances. This medication should be prescribed and monitored by healthcare professionals to optimize therapeutic outcomes and minimize adverse effects.